Boehringer Ingelheim receives ad-interim injunctions against four domestic pharma cos for diabetes drug

The recent four injunctions restrain domestic drugmakers from infringing the Patent of Linagliptin marketed under the trade name, ‘Trajenta’, in the country

Related Keywords

India ,Vani Manja ,Trajenta Linagliptin ,Jardiance Empagliflozin ,Optimus Pharma ,Emcure Pharmaceuticals For Linagliptin ,Boehringer Ingelheim ,High Court ,Boehringer Ingelheim India ,Eris Lifesciences ,Emcure Pharmaceuticals ,Injunctions ,Dharma ,